CAR+ Cell Enrichment & Assay Development

Enrich by linker type, without touching the target epitope

Enrichment is optional; when it is required, the choice of route directly affects recovery and the feasibility of downstream detection.

After transduction, CAR+ and CAR⁻ cells coexist in the population. For downstream killing or cytokine-release assays, negative cells dilute the effector signal; if only transduction efficiency is being assessed, measuring positivity is sufficient. This page addresses two questions: whether enrichment is needed, and which route to use.

 
CAR-X™ Solution  ›  This page

WHAT | What we offer

01 | CAR+ Cell Enrichment

Three anti-tag routes (G4S / Whitlow 218 / VHH) × two formats (direct nanobeads, indirect isolation kits). The recognition principle is the same as for detection antibodies, so detection and enrichment should follow the same linker route.

CAR+ Cell Enrichment Nanobeads (direct method)

Cat NoProduct NameDetails
GMLS-Tag003-Ab01-nanoIMBSOLIDEX®-ISOEx Anti-G4S Linker Nanobeads (Column-Based)Details
GMLS-Tag006-Ab01-nanoIMBSOLIDEX®-ISOEx Anti-Whitlow (218) Linker Nanobeads (Column-Based)Details
GMLS-Tag002-Ab01-nanoIMBSOLIDEX®-ISOEx Anti-VHH Nanobeads (Column-Based)Details

Indirect CAR+ Cell Isolation Kits (indirect method)

Cat NoProduct NameDetails
GMLS-Tag003-Ab01-kitSOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-based)Details
GMLS-Tag003-Ab01-kit-CFSOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-free)Details
GMLS-Tag006-Ab01-kitSOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-based)Details
GMLS-Tag006-Ab01-kit-CFSOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Isolation Kit (Column-free)Details
GMLS-Tag002-Ab01-kitSOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-based)Details
GMLS-Tag002-Ab01-kit-CFSOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-free)Details

WHY | When enrichment is needed and when it is not

Enrichment neededEnrichment not needed
Downstream functional assays (killing, cytokine release) require a defined effector populationOnly transduction efficiency is assessed; CAR% is sufficient
CAR positivity is low and the signal would be diluted by negative cellsPositivity already meets the experimental requirement
Parallel CAR+ and CAR⁻ controls are requiredSample size is small and cannot absorb sorting loss
A phenotypically defined batch is needed for cryopreservationCell number itself is the limiting factor

Important note: enrichment is not a required step in all CAR studies. Whether it is needed depends on the research question, CAR positivity, downstream assay design and the target cell population required.

HOW | Two enrichment routes

 Direct nanobead methodIndirect nanobead method
RecognitionAnti-tag nanobeads bind the CAR structure directlyBiotinylated anti-tag antibody + anti-biotin nanobeads
Labelling stepsOneTwo
ProductsAnti-G4S / Anti-Whitlow (218) / Anti-VHH NanobeadsSOLIDEX®-ISOEx Indirect Anti-… Isolation Kit
Separation formatColumn-basedColumn-based / Column-free
Epitope occupancyBeads occupy part of the epitope; a different antibody is recommended for subsequent detectionThe antibody occupies the epitope, which can be avoided by selecting a different clone
Suitable forRoutine enrichment with fewer stepsBead labelling interferes with downstream detection, or the recognition antibody must be changed

Route 1 (direct): ① select the anti-tag nanobeads matching the CAR construct → ② beads bind the CAR structure → ③ magnetic separation → ④ collect the CAR+ population

Route 2 (indirect): ① biotinylated anti-tag antibody binds the CAR → ② add anti-biotin nanobeads → ③ magnetic separation → ④ collect the CAR+ population

Steps | From starting cell preparation to post-enrichment detection

StepStageDescription
Step 1Starting CellsPBMC or another starting sample within the product's intended use
Step 2Immune Cell IsolationIsolate the target T / NK cells (untouched; target cells carry no antibody)
Step 3CAR EngineeringLentiviral transduction
Step 4CAR+ Cell Enrichment (optional)Choose the direct or indirect route according to the construct
Step 5CAR Expression & PhenotypingDetect with an antibody against an unoccupied epitope

FAQ

1How do I choose between the direct and indirect method?

Fewer steps: direct. If subsequent detection must avoid bead masking, or the recognition antibody must be changed, use indirect.

2What is the difference between Column-based and Column-free?

Column-based usually gives higher purity but takes longer; Column-free usually gives higher recovery and is faster to perform.

3Is the CAR epitope occupied after enrichment?

With the direct method yes; use a different epitope for subsequent detection. With the indirect method this can be avoided by changing the antibody clone.

4Do target cells carry antibody after untouched isolation?

No. Negative selection labels only non-target cells; target cells remain untouched.

5How much cell loss does enrichment cause?

It depends on starting cell number, CAR positivity and separation format; run a small-scale test separation before scaling up.

6Do the beads need to be released?

Depends on the downstream assay; refer to the corresponding product protocol if release is required.




<